PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 112 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,032,468 | +245.9% | 292,427 | +377.7% | 0.00% | – |
| Q2 2023 | $876,599 | -47.6% | 61,215 | -73.8% | 0.00% | – |
| Q1 2023 | $1,671,359 | +658.0% | 234,084 | +1091.1% | 0.00% | – |
| Q4 2022 | $220,507 | -78.6% | 19,653 | -78.9% | 0.00% | – |
| Q3 2022 | $1,030,000 | +0.4% | 93,000 | -23.4% | 0.00% | – |
| Q2 2022 | $1,026,000 | +33.6% | 121,412 | +115.3% | 0.00% | – |
| Q1 2022 | $768,000 | +239.8% | 56,400 | +391.9% | 0.00% | – |
| Q4 2021 | $226,000 | -80.3% | 11,466 | -67.9% | 0.00% | – |
| Q3 2021 | $1,146,000 | -57.9% | 35,710 | -55.6% | 0.00% | -100.0% |
| Q2 2021 | $2,721,000 | +747.7% | 80,374 | +841.0% | 0.00% | – |
| Q1 2021 | $321,000 | -20.0% | 8,541 | -29.3% | 0.00% | – |
| Q4 2020 | $401,000 | +63.0% | 12,076 | +79.8% | 0.00% | – |
| Q3 2020 | $246,000 | -20.1% | 6,716 | -43.8% | 0.00% | – |
| Q1 2020 | $308,000 | – | 11,948 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
| Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
| Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
| Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
| Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
| Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
| StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
| MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
| NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |